Speaker illustration

Doctor Hiroyoshi Yokoi

Fukuoka Sanno Hospital, Fukuoka (Japan)

Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices from Japan Post-Market Surveillance Study

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Intervention

Session: Lower Extremity Artery Revascularization in 2020

Thumbnail

Comparison of long DAPT versus short DAPT in Japanese PCI patients based on healthcare information database

Event: ESC Congress 2018

Topic: Big Data Analysis

Session: Atrial fibrillation, stroke and cardiovascular risk

Thumbnail

The Zilver PTX japanese post-market surveillance study of paclitaxel-eluting stents: 3 year results of the diabetic and in-stent restenosis subgroups

Event: ESC CONGRESS 2017

Topic: Peripheral arterial disease

Session: Vascular diseases - 3

Thumbnail

Impact of pioglitazone on cardiovascular events in patients with type-II diabetes mellitus after drug-eluting stent implantation

Event: ESC CONGRESS 2016

Topic: Diabetes management

Session: Improving diabetes outcomes: beyond glucocentricity

Thumbnail

Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 24-month results

Event: ESC CONGRESS 2016

Topic: Percutaneous / endovascular treatment

Session: Peripheral interventions

Thumbnail

Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices from Japan Post-Market Surveillance Study

Event: ESC Asia with APSC & AFC 2020

Topic: Intervention

Session: Abstract Programme

Thumbnail

This platform is supported by

logo Novo Nordisk